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Background
A recent report has indicated that transgenic expression of
HTLV-1 bZIP factor (HBZ) in CD4+ T cells induced T-
cell lymphomas and systemic inflammation in mice. How-
ever, there is limited information on in vivo expression of
HBZ in HTLV-1 infected individuals especially HAM/TSP.
Methods
We have generated rat and human monoclonal antibo-
dies against HBZ by hybridoma methodology and a
phage display system, and developed the ELISA system
for the detection of HBZ protein and anti-HBZ antibo-
dies. Using these reagents, we analyzed the expression
of HBZ protein in plasma and peripheral blood mono-
nuclear cells (PBMCs) of HTLV-1 infected individuals
as well as HTLV-1 infected cell lines. Then the results
were compared with the real time PCR data.
Results
Although we successfully detected HBZ protein in an
enforced overexpressed cells and HTLV-1 infected cell
lines by flow cytometry, ELISA, immunofluorescence
and immunoblotting, we could not detect HBZ protein
or anti-HBZ antibodies in HAM/TSP patients and
asymptomatic carrires (ACs) by our system. In contrast,
HBZ mRNA was significantly elevated in HAM/TSP
patients than ACs. Especially, rapidly progressive HAM/
TSP patients showed extremely high expression of HBZ
mRNA but not tax mRNA in their PBMCs.
Conclusions
These findings suggest that although expression of HBZ
protein was suppressed in vivo in HAM/TSP patients
and ACs, high expression of HBZ mRNA is closely asso-
ciated with the pathogenesis of HAM/TSP.
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